SCHEMBL824364

SCHEMBL824364

O=c1c2ccccc2nc2[nH]c3ccccc3n12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 1/20 0.54
KDM4E B2RXH2 7/20 0.52
NPC1 O15118 5/20 0.49
RAB9A P51151 5/20 0.49
HPGD P15428 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
LMNA P02545 4/20 0.49
TP53 P04637 3/20 0.49
HSD17B10 Q99714 3/20 0.49
ALDH1A1 P00352 5/20 0.48
ADORA1 P30542 2/20 0.47
PKM P14618 2/20 0.47
ADORA2A P29274 1/20 0.47
ADORA2B P29275 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
AURKA O14965 1/20 0.47
CYP1A1 P04798 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP1B1 Q16678 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11827448 0.88 KDM4E (0.55) CDC25BKDM4ENPC1RAB9AHPGD
SCHEMBL18053137 0.84 KDM4E (0.49) KDM4ENPC1RAB9AHPGDSMN1; SMN2
SCHEMBL30166463 0.84 KDM4E (0.49) KDM4ENPC1RAB9AHPGDSMN1; SMN2
SCHEMBL11826212 0.84 CYP1A1 (0.50) CDC25BKDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL11834181 0.83 CDC25B (0.47) CDC25BKDM4ENPC1RAB9AHPGD
SCHEMBL11822310 0.83 AURKA (0.49) CDC25BKDM4ENPC1RAB9AHPGD
SCHEMBL11823673 0.83 AURKA (0.52) CDC25BKDM4ENPC1RAB9AHPGD
SCHEMBL11836690 0.83 AURKA (0.49) CDC25BKDM4ENPC1RAB9AHPGD
SCHEMBL11821998 0.83 CYP1A1 (0.49) CDC25BKDM4ENPC1RAB9AHPGD
SCHEMBL11830081 0.83 AURKA (0.52) CDC25BKDM4ENPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3261759-B1 SELF-HEALING CAPACITOR AND METHODS OF PRODUCTION THEREOF CAPACITOR SCIENCES INC (US) 2020-05-06 EP disclosed
US-10347423-B2 Solid multilayer structure as semiproduct for meta-capacitor CAPACITOR SCIENCES INCORPORATED (US) 2019-07-09 US disclosed
US-10135003-B2 Materials for electronic devices MERCK PATENT GMBH (DE) 2018-11-20 US disclosed
US-RE47117-E1 Compensated in-plane switching mode liquid crystal display CRYSOPTIX K.K. (JP) 2018-11-06 US disclosed
US-20180114641-A1 SOLID MULTILAYER STRUCTURE AS SEMIPRODUCT FOR META-CAPACITOR CAPACITOR SCIENCES INCORPORATED 2018-04-26 US disclosed
US-20180114641-A1 SOLID MULTILAYER STRUCTURE AS SEMIPRODUCT FOR META-CAPACITOR CAPACITOR SCIENCES INCORPORATED 2018-04-26 US disclosed
US-9916931-B2 Energy storage devices and methods of production thereof CAPACITOR SCIENCE INCORPORATED (US) 2018-03-13 US disclosed
US-9916931-B2 Energy storage devices and methods of production thereof CAPACITOR SCIENCE INCORPORATED (US) 2018-03-13 US disclosed
US-9852846-B2 Self-healing capacitor and methods of production thereof CAPACITOR SCIENCES INCORPORATED (US) 2017-12-26 US disclosed
US-9852846-B2 Self-healing capacitor and methods of production thereof CAPACITOR SCIENCES INCORPORATED (US) 2017-12-26 US disclosed
WO-2009130676-A2 COLOR LIQUID CRYSTAL DISPLAY AND COMPENSATION PANEL CRYSOPTIX KK (JP) 2009-10-29 WO disclosed
US-20090268136-A1 Color Liquid Crystal Display and Compensation Panel CRYSOPTIX KK (JP) 2009-10-29 US disclosed
US-20090161037-A1 Backlight Module and Liquid Crystal Display Incorporating the Same CRYSOPTIX KK (JP) 2009-06-25 US disclosed
US-20090161037-A1 Backlight Module and Liquid Crystal Display Incorporating the Same CRYSOPTIX KK (JP) 2009-06-25 US disclosed
WO-2009037565-A2 COLOUR LIQUID CRYSTAL DISPLAY AND PATTERNED COMPENSATION PANEL CRYSOPTIX K.K. (GB) 2009-03-26 WO disclosed
WO-2008142635-A2 COMPENSATED IN-PLANE SWITCHING MODE LIQUID CRYSTAL DISPLAY CRYSOPTIX KK (GB) 2008-11-27 WO disclosed
WO-2007141025-A2 LIQUID CRYSTAL DISPLAY OPERATING IN A VERTICALLY ALIGNED MODE CRYSOPTIX K.K. (JP) 2007-12-13 WO disclosed
WO-2007122389-A2 BACKLIGHT MODULE AND LIQUID CRYSTAL DISPLAY INCORPORATING THE SAME CRYSOPTIX K.K. (JP) 2007-11-01 WO disclosed
US-4000275-A BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES ELI LILLY AND COMPANY (US) 1976-12-28 US disclosed
US-4000275-A BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES ELI LILLY AND COMPANY (US) 1976-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10135003-B2 Materials for electronic devices SCO2, AOC2, HCN2 CDC25B 1682/4885KDM4E 1163/4885NPC1 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.